文献速递炎症性肠病

青黛治疗溃疡性结肠炎患者的多中心随机对照试验疗效

Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
PubMed 文献 · Gastroenterology · 2017-11-22

这项多中心双盲试验将86例活动性溃疡性结肠炎患者随机分配至青黛0.5克、1.0克、2.0克或安慰剂组治疗8周,主要终点为第8周临床应答率。结果显示临床应答率呈显著剂量依赖性线性趋势,1.0克和2.0克组临床缓解率显著高于安慰剂组,但试验因外部原因终止,作者认为青黛因潜在不良事件包括肺动脉高压尚不应使用。

要点

  • 青黛0.5克、1.0克、2.0克组第8周临床应答率分别为69.6%、75.0%、81.0%,安慰剂组为13.6%,呈显著剂量依赖性线性趋势。
  • 1.0克组临床缓解率为55.0%,2.0克组为38.1%,均显著高于安慰剂组的4.5%。
  • 10例接受青黛治疗的患者出现轻度肝功能异常,未观察到严重不良事件。

核心结论

  • 8周青黛(每日0.5-2.0克)可有效诱导溃疡性结肠炎患者的临床应答。
  • 由于潜在不良事件包括肺动脉高压,青黛尚不应使用。

研究设计与样本

  • 多中心、双盲、随机对照试验,纳入日本86例活动性溃疡性结肠炎患者(Mayo评分6分或以上),入组时间为2016年3月30日至2016年12月27日。
  • 患者按1:1:1:1随机分配至青黛每日0.5克、1.0克、2.0克或安慰剂组,治疗8周。
  • 主要终点为第8周临床应答率,定义为Mayo评分降低3分且较基线降低至少30%,同时直肠出血亚评分降低至少1分或绝对直肠出血评分为0-1。
  • 主要次要终点为第8周临床缓解率,定义为Mayo评分≤2且无亚评分大于1。
  • 第8周同时评估黏膜愈合。

主要发现

  • 试验因外部原因终止:一例患者自行购买青黛使用6个月后报告肺动脉高压。
  • 意向治疗分析中,临床应答率:安慰剂组13.6%,青黛0.5克组69.6%,1.0克组75.0%,2.0克组81.0%,与安慰剂相比Cochran-Armitage趋势检验P<.0001。
  • 第8周临床缓解率:青黛1.0克组55.0%(P=.0004),2.0克组38.1%(P=.0093),均显著高于安慰剂组的4.5%。
  • 黏膜愈合率:安慰剂组13.6%,青黛0.5克组56.5%,1.0克组60.0%,2.0克组47.6%(与安慰剂相比P=.0278)。
  • 10例接受青黛治疗的患者出现轻度肝功能异常,未观察到严重不良事件。

临床怎么用

  • 作者认为8周青黛(每日0.5-2.0克)可有效诱导溃疡性结肠炎患者的临床应答。
  • 作者指出由于潜在不良事件包括肺动脉高压,青黛尚不应使用。

局限性

  • 试验因外部原因终止:一例患者自行购买青黛使用6个月后报告肺动脉高压。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Indigo naturalis (IN) is a traditional Chinese medicine that contains ligands for the aryl hydrocarbon receptor and promotes regeneration of the mucosa by inducing production of interleukin 22. IN might induce mucosal healing in patients with ulcerative colitis (UC). We performed a randomized controlled trial to investigate the safety and efficacy of IN in patients with UC. METHODS: We performed a multicenter, double-blind trial evaluating the safety of 86 patients in Japan with active UC (Mayo scores of 6 or more), enrolled from March 30 through December 27, 2016. Patients were randomly assigned to groups and given a daily dose of 0.5, 1.0, or 2.0 g IN or placebo (1:1:1:1 ratio) for 8 weeks. The primary endpoint was the rate of clinical response at week 8, defined as a 3-point decrease in the Mayo score and a decrease of at least 30% from baseline, with a decrease of at least 1 point for the rectal bleeding subscore or absolute rectal bleeding score of 0-1. The main secondary endpoint was the rate of clinical remission at week 8, defined as a Mayo score or ≤2 and no subscores with a value >1. Mucosal healing was also assessed at week 8. RESULTS: The trial was terminated because of an external reason: a report of pulmonary arterial hypertension in a patient who used self-purchased IN for 6 months. In the intent-to-treat analysis, we observed a significant, dose-dependent linear trend in proportions of patients with clinical responses (13.6% with a clinical response to placebo; 69.6% to 0.5 g IN; 75.0% to 1.0 g IN; and 81.0% to 2.0 g IN) (Cochran-Armitage trend test P < .0001 compared with placebo). Proportions of patients in clinical remission at week 8 were significantly higher in the 1.0 g IN group (55.0%, P = .0004) and the 2.0 g IN group (38.1%, (P = .0093) than in the placebo group (4.5%). Proportions of patients with mucosal healing were 13.6% in the placebo group, 56.5% in the 0.5 g IN group, 60.0% in the 1.0 g IN group, and 47.6% in the 2.0 g IN group (P = .0278 compared with placebo). Although mild liver dysfunction was observed in 10 patients who received IN, no serious adverse events were observed. CONCLUSIONS: In a randomized, placebo-controlled trial, we found 8 weeks of IN (0.5-2.0 g per day) to be effective in inducing a clinical response in patients with UC. However, IN should not yet be used because of the potential for adverse effects, including pulmonary arterial hypertension. Clinical Trials Registry no: UMIN000021439 (http://www.umin.ac.jp/ctr/).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Naganuma M, Sugimoto S, Mitsuyama K, et al. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. Gastroenterology. 2017. PMID: 29174928. doi:10.1053/j.gastro.2017.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。